Last reviewed · How we verify

Winrevair — Competitive Intelligence Brief

Winrevair (SOTATERCEPT) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Cardiovascular.

marketed Cardiovascular Recombinant protein Live · refreshed every 30 min

Target snapshot

Winrevair (SOTATERCEPT) — Merck Sharp Dohme. Winrevair works by binding to and inhibiting the activity of activin receptors, which play a role in the development of pulmonary arterial hypertension.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Winrevair TARGET SOTATERCEPT Merck Sharp Dohme marketed 2025-01-01

Recent regulatory actions (last 90 days)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Winrevair — Competitive Intelligence Brief. https://druglandscape.com/ci/sotatercept. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: